All Blogs
Nov 07, 2025
Bayer’s Lynkuet Ushers in New Class of Therapies for Menopause
After a brief delay earlier this year, and following its world-first approval in the UK over the summer, Bayer has now secured FDA approval for its novel therapy, expanding the limited range of nonhormonal options available for managing common menopausal symptoms. The FDA has approved Bayer’s dual neurokinin (NK) i...
Read More...
Nov 06, 2025
Nexalin Technology Secures Israeli Regulatory Clearance for Gen-2 SYNC 15 mA DIFS™ Neurostimulation System; W&H Medical Launches First U.S.–Cleared Piezo & Drill Combo Console for Rhinoplasty & Facial Surgery; Elevaris Launches CDMO Services and Procedural Needle Offerings in EMEA; Cardinal Health Successfully Acquired Solaris Health; 4WEB Medical Sets a New Standard in Implant-Based Therapy; BD Reaches Key Milestone in AGILITY Trial Evaluating Revello™ Vascular Covered Stent for PAD
Nexalin Technology Announced Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel On October 30, 2025, Nexalin Technology, Inc., a company recognized for its Deep Intracranial Frequency Stimulation (DIFS™) technology, announced that its Gen-2 Console (“SYNC”) 15 mA neurosti...
Read More...
Nov 05, 2025
AI Hospitals of the Future–Where Robotics, Predictive Analytics, and Compassion Converge
The global healthcare landscape is undergoing one of the most transformative revolutions in modern history. At the heart of this evolution lies Artificial Intelligence (AI), a force that is not just augmenting medical workflows but reshaping how hospitals function, how care is delivered, and how humanity interacts ...
Read More...
Nov 04, 2025
Intensity Therapeutics Publishes Compelling Clinical Data for INT230-6 in Advanced Cancers; UCB Wins FDA Approval for KYGEVVI for Rare Mitochondrial Disease TK2d; BrainXell Therapeutics Unveils Promising Preclinical Data for iPSC-Derived Neuronal Therapy in Parkinson’s Disease; CARsgen Therapeutics Reports Encouraging Clinical Data for Allogeneic CAR-T Products in Hematologic Malignancies; Novo Nordisk’s $9 Billion Counterbid for Metsera Ignites Landmark Obesity Drug Market Battle
Intensity Therapeutics Publishes Compelling Clinical Data for INT230-6 in Advanced Cancers Intensity Therapeutics, Inc. (Nasdaq: INTS) announced the publication of its Phase 1/2 clinical results for INT230-6. The comprehensive study evaluated the intratumoral therapy's safety, efficacy, and mechanism of action a...
Read More...
Oct 31, 2025
Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer
In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025,...
Read More...
Nov 03, 2025
New Lupus Nephritis Drugs on the Horizon: 6 Promising Therapies Eyeing Newly Approved GAZYVA’s Market Space
Roche’s GAZYVA FDA approval has already rewritten the lupus nephritis playbook — it turned a long-standing oncology B-cell drug into a validated, kidney-saving option. It proved that aggressive B-cell targeting can materially boost complete renal responses when added to standard therapy. The GAZYVA approval (driven...
Read More...
Oct 30, 2025
Zimmer Biomet Wins FDA Breakthrough Status for Iodine-Treated Hip Implant; Terumo Gains U.S. Clearance for OPUSWAVE® System and DualView® Catheter; Medtronic’s Symplicity Spyral RDN Device Added to CMS National Coverage; West Launches Synchrony™ PFS System at CPHI; Emboline Completes U.S. Pivotal IDE Trial Enrollment for Emboliner® Device; Laborie Completes First Procedures in ENDURE 1 Trial with Optilume® Balloon
Zimmer Biomet Announced FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System On October 28, 2025, Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that the FDA had granted breakthrough device designation for its groundbreaking iodine-treat...
Read More...
Oct 29, 2025
Artificial Intelligence in Drug Commercialization: Accelerating Market Success through Data-Driven Precision
The pharmaceutical industry is undergoing a paradigm shift, as Artificial Intelligence (AI) becomes a central force in transforming every stage of the drug lifecycle, from discovery to post-market performance. Among its most disruptive applications, AI in drug commercialization is redefining how therapies are...
Read More...
Oct 28, 2025
Syndax Pharmaceuticals Receives FDA Approval for REVUFORJ; FDA Approves BLENREP for Adults with Relapsed/Refractory Multiple Myeloma; Novartis to Acquire Avidity for $12 Billion; BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study; Eli Lilly to Acquire Adverum Biotechnologies
Syndax Pharmaceuticals Receives Approval for REVUFORJ from the FDA Syndax Pharmaceuticals announced that the FDA has approved REVUFORJ (revumenib) for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and old...
Read More...
Oct 27, 2025
Roche’s GAZYVA Extends Indications Into Lupus, Strengthening Immunology Pipeline
As the lupus treatment landscape undergoes major changes, Roche is entering the US lupus nephritis market with a fresh FDA approval for its long-standing blood cancer drug, GAZYVA. On October 20, 2025, Roche’s Genentech division announced that the FDA had approved GAZYVA (obinutuzumab) for use in adults with active...
Read More...